Tandem Diabetes (TNDM) Tops Q1 EPS by 8c, Revenues Beat; Offers FY21 Revenues Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tandem Diabetes Care Announces First Quarter 2021 Financial Results and Updated Full Year 2021 Sales Guidance
May 5, 2021 4:05 PM EDTSAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2021 and updated its sales guidance for the year ending December 31, 2021.
First Quarter 2021 Highlights
In comparing the first quarter of 2021 to the same period of 2020:
Worldwide pump shipments increased 46 percent to 25,352 pumps from 17,378 pumps Sales increased 44 percent to $141.0 million from $97.9 million Gross margin improved to 52 percent of sales from 51 percent Operating margin... More